LON:NCYT Novacyt (NCYT) Share Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free NCYT Stock Alerts GBX 67 -3.00 (-4.29%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range 64.77▼ 73.3050-Day Range 43▼ 7052-Week Range 35.80▼ 86Volume294,431 shsAverage Volume73,452 shsMarket Capitalization£47.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Novacyt alerts: Email Address Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Novacyt Stock (LON:NCYT)Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.Read More NCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NCYT Stock News HeadlinesApril 19, 2024 | actusnews.comDHSC Claim update - Pre-Trial ReviewApril 13, 2024 | lse.co.ukAstraZeneca increases 2024 dividend by 7%April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 11, 2024 | actusnews.comDirectorate Changes and FY 23 results updateFebruary 6, 2024 | actusnews.comUpdate on Taiwanese divestmentJanuary 30, 2024 | morningstar.comNovacyt SA NYZJanuary 25, 2024 | actusnews.comTrading updateSeptember 30, 2023 | actusnews.comReminder to shareholders re. AGM votingApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.September 11, 2023 | actusnews.comCancellation of trading of Yourgene SharesAugust 29, 2023 | actusnews.comNotice of rescheduled AGMJuly 3, 2023 | proactiveinvestors.comYourgene jumps 143% on Novacyt £16.7m knock-out bidJune 24, 2023 | lse.co.ukChipotle Mexica Share ChatJune 14, 2023 | lse.co.ukNordtelekom Nyr Share ChatJune 12, 2023 | lse.co.ukCalipso Oradea Share ChatMay 26, 2023 | actusnews.comPublication of Annual Report and AGM votingJanuary 30, 2023 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): DHSC Claim Update – Trial Date ListedJanuary 26, 2023 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group") Full Year 2022 Trading UpdateDecember 7, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Non-Executive Director ChangeDecember 6, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of genesig® COVID-19 3G PCR Test in the UK Under CTDA LegislationNovember 10, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Directorate ChangeOctober 26, 2022 | proactiveinvestors.comNovacyt gains UK approval for its multiplex PCR test for detection of winter virusesOctober 26, 2022 | proactiveinvestors.comNovacyt approved for COVID and winter viruses PCR testOctober 10, 2022 | thetimes.co.ukYour three-minute digest - The TimesOctober 10, 2022 | marketscreener.comNovacyt Faces $150 Million Legal Claim For Inconsistent COVID-19 Testing Results In UK - Marketscreener.comOctober 9, 2022 | thetimes.co.ukNovacyt subject to legal claim after 'troubling' Covid test results - The TimesOctober 6, 2022 | businesswire.comOutlook on the High-Resolution Melting Analysis Global Market to 2027 - Featuring Agilent Technologies, Azura Genomics, Illumina and Novacyt Among Others - ResearchAndMarkets.com - Business WireSee More Headlines Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:NCYT CUSIPN/A CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-25,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-21.08% Return on Assets-5.88% Debt Debt-to-Equity Ratio0.36 Current Ratio5.09 Quick Ratio4.46 Sales & Book Value Annual Sales£7.87 million Price / Sales6.08 Cash FlowGBX 116.64 per share Price / Cash Flow0.58 Book ValueGBX 152 per share Price / Book0.45Miscellaneous Outstanding Shares70,630,000Free FloatN/AMarket Cap£47.82 million OptionableNot Optionable Beta-1.73 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. James Martin McCarthy (Age 58)Acting CEO & Director Comp: $354.52kMr. Steve GibsonCFO & DirectorBryan CloseChief Operations OfficerMs. Mandy CowlingCorporate & Investor Relations ManagerMr. David FranksChief Human Resources OfficerPaul OladimejiGroup Head of R&DMr. Lyn Dafydd Rees (Age 51)Executive Director More ExecutivesKey CompetitorsIntelligent Ultrasound GroupLON:IUGInspiration Healthcare GroupLON:IHCBelluscuraLON:BELLCreo Medical GroupLON:CREOEKF DiagnosticsLON:EKFView All Competitors NCYT Stock Analysis - Frequently Asked Questions How have NCYT shares performed in 2024? Novacyt's stock was trading at GBX 61.50 at the beginning of the year. Since then, NCYT shares have increased by 8.9% and is now trading at GBX 67. View the best growth stocks for 2024 here. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN). How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:NCYT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
